11.3. The Advisory Committee recommended that avalglucosidase alfa for the treatment of late onset Pompe disease be funded with a medium priority.

Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year Galafold®Q3 Revenue of $120.4M, up 20% Year-over-Year PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: ...

Drug–drug interactions between antidiabetic agents and other pharmacological compounds may be two-sided. For those antidiabetic drugs that are metabolized via the CYP450 isoenzymes, concomitant ...

Figure 3. Summary of pathogenicity-related genes annotations. (A) Carbohydrate-active enzymes (CAZys). (B) Membrane transport proteins (top 10). (C) Pathogen-host Interaction related genes (PHIs). (D) ...